Van ECK Associates Corp Increases Stock Position in DexCom, Inc. (NASDAQ:DXCM)

Van ECK Associates Corp grew its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 325.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 85,813 shares of the medical device company’s stock after purchasing an additional 65,622 shares during the period. Van ECK Associates Corp’s holdings in DexCom were worth $6,674,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the stock. Versant Capital Management Inc acquired a new position in DexCom in the 4th quarter worth approximately $25,000. Heck Capital Advisors LLC bought a new stake in DexCom in the fourth quarter worth approximately $38,000. MassMutual Private Wealth & Trust FSB increased its position in DexCom by 46.7% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 833 shares of the medical device company’s stock worth $65,000 after buying an additional 265 shares during the last quarter. RPg Family Wealth Advisory LLC acquired a new position in shares of DexCom during the 3rd quarter valued at about $57,000. Finally, Park Place Capital Corp grew its holdings in DexCom by 3,516.7% during the fourth quarter. Park Place Capital Corp now owns 868 shares of the medical device company’s stock valued at $68,000 after purchasing an additional 844 shares during the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, EVP Sadie Stern sold 4,259 shares of the stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total transaction of $318,275.07. Following the completion of the transaction, the executive vice president now directly owns 71,192 shares in the company, valued at $5,320,178.16. This represents a 5.64 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, COO Jacob Steven Leach sold 2,634 shares of DexCom stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $228,920.94. Following the completion of the sale, the chief operating officer now directly owns 268,644 shares in the company, valued at approximately $23,347,850.04. This represents a 0.97 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 42,342 shares of company stock worth $3,628,069. 0.30% of the stock is owned by insiders.

DexCom Trading Up 5.9 %

NASDAQ DXCM opened at $89.07 on Tuesday. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12. DexCom, Inc. has a one year low of $62.34 and a one year high of $142.00. The stock’s 50-day moving average is $82.44 and its 200-day moving average is $75.49. The firm has a market cap of $34.79 billion, a P/E ratio of 53.34, a P/E/G ratio of 2.26 and a beta of 1.14.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 17.22% and a return on equity of 31.40%. Sell-side analysts anticipate that DexCom, Inc. will post 1.69 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the stock. JPMorgan Chase & Co. boosted their target price on shares of DexCom from $75.00 to $85.00 and gave the stock a “neutral” rating in a research report on Friday, October 25th. Oppenheimer lowered their target price on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating on the stock in a report on Friday, October 25th. Morgan Stanley boosted their price objective on DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a research note on Friday. Redburn Atlantic upgraded shares of DexCom from a “neutral” rating to a “buy” rating and upped their target price for the stock from $85.00 to $115.00 in a research report on Monday, February 3rd. Finally, Citigroup raised their price target on DexCom from $85.00 to $91.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. Four analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $99.06.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.